Zoloft Articles
GSK fills product gap by licensing Merck KGaA antidepressant
15 February 2001
40%-123% US Rx price variations found
13 February 2001
European psychotropics market forecasts
22 January 2001
Controversial Canadian patent policy upheld
9 January 2001
Falling US sales for high-profile drugs
8 November 2000
Seroxat effective in PTSD; Czech approval
14 September 2000
Pfizer leads 1st-qtr US physician detailing
11 July 2000
Pfizer sues Ivax over Zoloft
3 April 2000
Call to drug firms over HMO pill-splitting
27 March 2000
US HMO members told: "cut pills in half"
20 March 2000
Prozac losing place as USA's leading drug
8 March 2000
Pfizer EPS in 4th qtr rises 56%
18 January 2000
FDA backs first PTSD drug, Pfizer's Zoloft
9 December 1999
Pfizer gains FDA committee OK for Zoloft in PTSD
12 October 1999
World's top-selling drugs; 2002 forecasts
13 August 1999
P&U's reboxetine is "approvable" in USA
3 August 1999
Pfizer Aims For Top Slot After Millenium
10 November 1998
US Majors Post Strong Earnings For 3rd Quarter
15 October 1998
"Extraordinary"Viagra Sales Lift Pfizer Earnings
10 July 1998
USA's Most-Dispensed Rx Drugs In April 1998
20 May 1998
CNS Generics "Battle Imminent"
21 April 1998
Pfizer Posts Double-Digit Sales & Earnings Growth
15 April 1998
Expanded Warnings For J&J's Hismanal
11 February 1998
3rd-Qtr Rx Drug Prices Up 2.9%, Generics Fall 6.4%
25 November 1997
Drug Promo Meetings "Up 61% Since 1995"
27 October 1997
Pfizer's Healthy Growth Lifted By Alliance Products
16 October 1997
Pediatric Approval For Pfizer's Zoloft
16 October 1997
GW's Zantac Knocked Off Top US Rx Drug Spot
4 September 1997
Pfizer Enters New Product Cycle With Strong Potential
7 August 1997
Zoloft Becomes 2nd SSRI Cleared For Panic
23 July 1997
Pfizer's Good Volume Growth Marred By Strong $
17 July 1997
Pfizer Gets AAA Ranking From S&P
12 June 1997
High SSRI Link To Sexual Dysfunction
5 May 1997
Forex Impacts Sales At Pfizer, Merck And S-P
22 April 1997
US Rx Wholesale Prices "Up 1.8% In 1996"
3 March 1997
US Rx Drug Sales For 1996 Up 10% At $85.35 Billion
24 February 1997
New Bulimia Indication For Prozac In USA
2 December 1996
Zoloft Gets OCD Indication
4 November 1996
Net Income Rises 21% in 3rd Qtr At Pfizer
21 October 1996
Pfizer Rapped Over Zoloft Clams
19 August 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
Pfizer Rapped Over ADR Reporting
27 May 1996
1st-Qtr Sales Driven By New Products At Pfizer
22 April 1996
Losec "Will Be The World's Top-Selling Drug In 2000"
26 February 1996
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
Antidepressant Growth "Well Above Average"
22 January 1996
Pfizer Presents Fertile Pipeline
6 November 1995
US 3rd Qrt Results: Strong Gains For Pfizer, Lilly
23 October 1995
Pfizer Expects A Strong Performance In 1995
2 October 1995
US Sales of Generic Drugs Up 29% In 1994, Says IMS
17 July 1995
Solid 2nd Qtr Earnings Growth For US Drugmakers
17 July 1995
Growth Forecasts For Antidepressant Drugs
8 May 1995
Serzone Priced At Discount To SSRIs In USA
16 January 1995
Pfizer: Record Number Of Drugs In Phases II & III
31 October 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
CURRENCIES STILL A FACTOR IN US 1st QTR
2 May 1994
NEW PLAYER IN US DEPRESSION MARKET
25 April 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
NEW APPROVALS CHANGE DEPRESSION MARKET
17 January 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
WORLD MARKETS FOR CNS AND GASTROINTESTINALS
13 December 1993
ADVANCES BY US DRUG COMPANIES IN 2nd QTR
26 July 1993
ANALYSTS LOWER PFIZER RATING
5 July 1993
US PRESCRIBING TRENDS IN MARCH
28 June 1993
SB AND J&J TO COPROMOTE IN USA
24 May 1993
HHS RECOMMENDATIONS FOR ANTIDEPRESSANTS
3 May 1993
PFIZER "CONFIDENT" IN CHANGING ENVIRONMENT
3 May 1993
NEUROPHARMACEUTICAL MARKET IN USA
19 April 1993
PFIZER CONSIDERS PRICE CUTS
29 March 1993
DOUBLE TROUBLE FOR SMITHKLINE BEECHAM
22 March 1993
FDA YEAR-END DRUG APPROVALS ROLL-OUT
4 January 1993
FDA PANEL BACKS PAROXETINE APPROVAL
12 October 1992
IMPROVEMENTS IN 1ST QTR FOR US FIRMS
20 April 1992
DEPRESSION: THE COST TO SOCIETY
6 April 1992
DEPRESSION: THE COST TO SOCIETY
6 April 1992
STOCK MARKET COMMENTARY: NEW YORK
9 March 1992
US FDA BEATS 1990 DRUG APPROVALS IN 1991
13 January 1992
YEAR-END FDA APPROVALS
6 January 1992
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
